Strategic Pharma Partnerships Muna has established a research alliance with GlaxoSmithKline to identify and validate novel drug targets for Alzheimer's disease, highlighting strong pharma interest in its Trem2-focused platform and creating potential paths for co-development, licensing, or joint programs with big pharma.

Funding Momentum External validation from grants underscores Muna's credibility and funding runway: The Michael J. Fox Foundation awarded a $4.9 million grant in 2022 for Parkinson's-related work, and in 2026 the Alzheimer's Association granted $1 million to advance Trem2-targeting therapy.

TREM2 Platform The company is advancing Trem2 agonists with potential applications across neurodegenerative and inflammatory conditions, suggesting a versatile platform that could attract cross-indication collaborations or licensing deals with partners seeking novel CNS targets.

European Growth Footprint Copenhagen-based private company with 51-200 employees and a measured revenue base positions Muna for European business development, including partnerships with regional CROs and potential licensing conversations with global biopharma.

Disease Focus & Value Muna targets Alzheimer’s disease, Frontotemporal Dementia, and Parkinson’s to slow or stop neurodegeneration and preserve cognition, presenting a strong patient-centric value proposition for partnerships focused on disease modification, risk sharing, and milestone-driven deals.